From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma - Summary - MDSpire

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma

  • By

  • Jean-Baptiste Barbe-Richaud

  • Hélène Cebula

  • Julien Todeschi

  • Marie des Neiges Santin

  • Seyyid Baloglu

  • Roland Schott

  • Mathieu Cotton

  • Aurélien Blouet

  • Maxime Bobin

  • Georges Noël

  • Laura Somme

  • June 23, 2026

  • 0 min

Share

Objective:

To ascertain the most effective therapeutic strategy concerning overall survival (OS) at the initial recurrence of glioblastoma.

Approach:
    Key Findings:
    • Tumor recurrence occurs in approximately 75% of individuals within a year of diagnosis.
    • Median overall survival for recurrent GBM is under 2 years.
    • Limited information exists on the comparison of various strategies for managing recurrence.
    Interpretation:

    The study aims to provide insights into the effectiveness of different therapeutic strategies for recurrent glioblastoma, focusing on overall survival outcomes.

    Limitations:
    • The study is retrospective and conducted at two institutions, which may limit generalizability.
    • Exclusion of patients with IDH-mutant GBM and secondary GBM may affect the applicability of findings.
    Conclusion:

    The FROST study seeks to clarify the impact of multimodal versus singular therapeutic methods on survival outcomes in recurrent glioblastoma patients.

Original Source(s)

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma

  • by Jean-Baptiste Barbe-Richaud, Hélène Cebula, Julien Todeschi, Marie des Neiges Santin, Seyyid Baloglu, Roland Schott, Mathieu Cotton, Aurélien Blouet, Maxime Bobin, Georges Noël, Laura Somme

  • June 23, 2026

Related Content

Liquid Biopsy in Pediatric Acute Lymphoblastic Leukemia (ALL)

Leveraging Large Language Models to Integrate Clinical Knowledge and Machine Learning Predictions for Lymph Node Metastasis Prediction: Development of a Knowledge-Augmented Framework

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies